Table 7.
Clearance rates by pfcrt mutation at baseline in study A0661126 (Colombia/Suriname)
| pfcrt mutation at baseline | AZCQ 1 g (n = 114)
|
AZCQ 500 mg (n = 14)
|
AP (n = 116)
|
|---|---|---|---|
| n/N (%) | n/N (%) | n/N (%) | |
| CQ sensitive | 0/1 (0) | 3/3 (100) | – |
| CVMNK | 0/1 (0) | 3/3 (100) | – |
| CQ resistant | 67/101 (66) | 3/7 (43) | 104/104 (100) |
| CVMET | 38/38 (100) | 2/2 (100) | 38/38 (100) |
| SVMNT | 29/63 (46) | 1/5 (20) | 66/66 (100) |
| Negative | – | – | 1/1 (100) |
| Othersa | 8/8 (100) | 4/4 (100) | 6/6 (100) |
Notes: n, number of subjects cleared at Day 28; N, number of subjects with the respective mutations at baseline; CVMET, South American origin; CVMNK, wild type; SVMNT, South American origin.
a
Others included P. vivax or missing sample.
Abbreviations: AP, atovaquone–proguanil; AZCQ, azithromycin–chloroquine; CQ, chloroquine; P. falciparum, Plasmodium falciparum; pfcrt, P. falciparum chloroquine resistance transporter gene; P. vivax, Plasmodium vivax.